Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Prime Medicine (PRME) EBITDA Margin (2024 - 2025)

Prime Medicine filings provide 2 years of EBITDA Margin readings, the most recent being 5492.84% for Q4 2025.

  • On a quarterly basis, EBITDA Margin fell 355532.0% to 5492.84% in Q4 2025 year-over-year; TTM through Dec 2025 was 4340.7%, a 222538.0% increase, with the full-year FY2025 number at 4340.7%, up 222538.0% from a year prior.
  • EBITDA Margin hit 5492.84% in Q4 2025 for Prime Medicine, down from 4125.63% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 1937.52% in Q4 2024 to a low of 25084.21% in Q3 2024.